BioXcel Therapeutics Inc. (NASDAQ: BTAI) announced that its SERENITY At-Home Pivotal Phase 3 trial met its primary safety endpoint for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE